2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

small cell lung carcinoma (SCLC)

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W002864
    6-Bromonicotinic acid

    		Drug Intermediate Others
    6-Bromonicotinic acid is a brominated derivative of Niacin (HY-B0143), can be used as a drug intermediate for the synthesis of Anabaseine (HY-115766) derivatives.
    6-Bromonicotinic acid
  • HY-175757
    HsClpP activator-2

    		ClpP Apoptosis Reactive Oxygen Species (ROS) Cancer
    HsClpP activator-2 is an orally active HsClpP agonist with a KD of 40 nM. HsClpP activator-2 potently inhibits SCLC cells including H69 (IC50 = 0.17 μM) and H82 (IC50 = 0.19 μM). HsClpP activator-2 disrupts mitochondrial membrane potential (MMP), as well as induces apoptosis and ROS in H82 cells. HsClpP activator-2 significantly inhibits tumor growth in non-SMC xenograft models with a tumor growth inhibition. HsClpP activator-2 can be used for the study of small cell lung carcinoma (SCLC) .
    HsClpP activator-2
  • HY-P991731
    Alveltamig

    ZG006

    		 CD3 Cancer
    Alveltamig (ZG006) is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3. Alveltamig has two distinct DLL3 epitopes, and bridges tumor cells and T cells by strongly binding to DLL3 on tumor cells and CD3 on T cells, thereby mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the study of small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC) .
    Alveltamig
  • HY-177572
    YL201

    		Antibody-Drug Conjugates (ADCs) CD276/B7-H3 Cancer
    YL201 is an antibody-drug conjugate (ADC) targeting B7H3. YL201 comprises a human anti-B7H3 monoclonal antibody Tambotatug (HY-P991719), a protease-cleavable linker DL-01 (HY-155870) or DL-01 formic (HY-155870A), and a topoisomerase 1 inhibitor payload. YL201 can be used for the study of B7H3-expressing advanced solid tumors, with a focus on extensive-stage small cell lung cancer (ES-SCLC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer, esophageal squamous cell carcinoma .
    YL201

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: